Recro Pharma, Inc. (REPH) Stock Competitors & Peer Comparison
See (REPH) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| REPH | $2.09 | -0.48% | 177.4M | -8.04 | -$0.26 | N/A |
| TAK | $15.87 | +0.83% | 49.7B | 41.37 | $0.38 | +3.96% |
| HLN | $9.07 | +1.97% | 40.3B | 18.61 | $0.49 | +2.13% |
| TEVA | $34.20 | +2.83% | 40.1B | 25.71 | $1.34 | N/A |
| VTRS | $16.42 | +3.04% | 18.9B | -54.00 | -$0.30 | +3.04% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.22 | +2.28% | 12.2B | -49.00 | -$0.50 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.33 | +0.72% | 11.1B | 24.76 | $0.54 | +0.69% |
| RGC | $20.34 | -4.91% | 10B | -2031.00 | -$0.01 | N/A |
Stock Comparison
REPH vs TAK Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TAK has a market cap of 49.7B. Regarding current trading prices, REPH is priced at $2.09, while TAK trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TAK's P/E ratio is 41.37. In terms of profitability, REPH's ROE is -0.22%, compared to TAK's ROE of +0.03%. Regarding short-term risk, REPH is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TAK's competition here
REPH vs HLN Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HLN has a market cap of 40.3B. Regarding current trading prices, REPH is priced at $2.09, while HLN trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HLN's P/E ratio is 18.61. In terms of profitability, REPH's ROE is -0.22%, compared to HLN's ROE of +0.17%. Regarding short-term risk, REPH is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check HLN's competition here
REPH vs TEVA Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TEVA has a market cap of 40.1B. Regarding current trading prices, REPH is priced at $2.09, while TEVA trades at $34.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TEVA's P/E ratio is 25.71. In terms of profitability, REPH's ROE is -0.22%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, REPH is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TEVA's competition here
REPH vs VTRS Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, REPH is priced at $2.09, while VTRS trades at $16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas VTRS's P/E ratio is -54.00. In terms of profitability, REPH's ROE is -0.22%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, REPH is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check VTRS's competition here
REPH vs ITCI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, REPH is priced at $2.09, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ITCI's P/E ratio is -180.64. In terms of profitability, REPH's ROE is -0.22%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, REPH is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ITCI's competition here
REPH vs ELAN Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, REPH is priced at $2.09, while ELAN trades at $24.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ELAN's P/E ratio is -49.00. In terms of profitability, REPH's ROE is -0.22%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, REPH is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ELAN's competition here
REPH vs CTLT Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, REPH is priced at $2.09, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CTLT's P/E ratio is -27.84. In terms of profitability, REPH's ROE is -0.22%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, REPH is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CTLT's competition here
REPH vs RDY Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RDY has a market cap of 11.1B. Regarding current trading prices, REPH is priced at $2.09, while RDY trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RDY's P/E ratio is 24.76. In terms of profitability, REPH's ROE is -0.22%, compared to RDY's ROE of +0.12%. Regarding short-term risk, REPH is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check RDY's competition here
REPH vs RGC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RGC has a market cap of 10B. Regarding current trading prices, REPH is priced at $2.09, while RGC trades at $20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RGC's P/E ratio is -2031.00. In terms of profitability, REPH's ROE is -0.22%, compared to RGC's ROE of -2.32%. Regarding short-term risk, REPH is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check RGC's competition here
REPH vs LNTH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, REPH is priced at $2.09, while LNTH trades at $103.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LNTH's P/E ratio is 23.86. In terms of profitability, REPH's ROE is -0.22%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, REPH is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check LNTH's competition here
REPH vs INDV Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, REPH is priced at $2.09, while INDV trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas INDV's P/E ratio is 19.62. In terms of profitability, REPH's ROE is -0.22%, compared to INDV's ROE of -1.42%. Regarding short-term risk, REPH is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check INDV's competition here
REPH vs AMRX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AMRX has a market cap of 4.7B. Regarding current trading prices, REPH is priced at $2.09, while AMRX trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AMRX's P/E ratio is 39.70. In terms of profitability, REPH's ROE is -0.22%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, REPH is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AMRX's competition here
REPH vs SUPN Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, REPH is priced at $2.09, while SUPN trades at $45.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SUPN's P/E ratio is -89.53. In terms of profitability, REPH's ROE is -0.22%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, REPH is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SUPN's competition here
REPH vs DCPH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, REPH is priced at $2.09, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DCPH's P/E ratio is -11.58. In terms of profitability, REPH's ROE is -0.22%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, REPH is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check DCPH's competition here
REPH vs AVDL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, REPH is priced at $2.09, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, REPH's ROE is -0.22%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, REPH is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AVDL's competition here
REPH vs BHC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BHC has a market cap of 1.9B. Regarding current trading prices, REPH is priced at $2.09, while BHC trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BHC's P/E ratio is -1.60. In terms of profitability, REPH's ROE is -0.22%, compared to BHC's ROE of +1.21%. Regarding short-term risk, REPH is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check BHC's competition here
REPH vs EMBCV Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, REPH is priced at $2.09, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EMBCV's P/E ratio is N/A. In terms of profitability, REPH's ROE is -0.22%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, REPH is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check EMBCV's competition here
REPH vs HCM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HCM has a market cap of 1.9B. Regarding current trading prices, REPH is priced at $2.09, while HCM trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HCM's P/E ratio is 4.01. In terms of profitability, REPH's ROE is -0.22%, compared to HCM's ROE of +0.41%. Regarding short-term risk, REPH is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check HCM's competition here
REPH vs ANIP Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, REPH is priced at $2.09, while ANIP trades at $81.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ANIP's P/E ratio is 20.77. In terms of profitability, REPH's ROE is -0.22%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, REPH is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ANIP's competition here
REPH vs DVAX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, REPH is priced at $2.09, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DVAX's P/E ratio is -41.89. In terms of profitability, REPH's ROE is -0.22%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, REPH is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check DVAX's competition here
REPH vs TARO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, REPH is priced at $2.09, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TARO's P/E ratio is 30.05. In terms of profitability, REPH's ROE is -0.22%, compared to TARO's ROE of +0.03%. Regarding short-term risk, REPH is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TARO's competition here
REPH vs PRGO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, REPH is priced at $2.09, while PRGO trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PRGO's P/E ratio is -0.86. In terms of profitability, REPH's ROE is -0.22%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, REPH is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PRGO's competition here
REPH vs ALVOW Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALVOW has a market cap of 1.4B. Regarding current trading prices, REPH is priced at $2.09, while ALVOW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALVOW's P/E ratio is N/A. In terms of profitability, REPH's ROE is -0.22%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, REPH is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ALVOW's competition here
REPH vs PAHC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, REPH is priced at $2.09, while PAHC trades at $31.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PAHC's P/E ratio is 14.01. In terms of profitability, REPH's ROE is -0.22%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, REPH is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PAHC's competition here
REPH vs ALVO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, REPH is priced at $2.09, while ALVO trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALVO's P/E ratio is 41.60. In terms of profitability, REPH's ROE is -0.22%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, REPH is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ALVO's competition here
REPH vs HROW Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, REPH is priced at $2.09, while HROW trades at $39.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HROW's P/E ratio is -88.05. In terms of profitability, REPH's ROE is -0.22%, compared to HROW's ROE of -0.34%. Regarding short-term risk, REPH is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check HROW's competition here
REPH vs COLL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, REPH is priced at $2.09, while COLL trades at $34.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas COLL's P/E ratio is 16.70. In terms of profitability, REPH's ROE is -0.22%, compared to COLL's ROE of +0.27%. Regarding short-term risk, REPH is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check COLL's competition here
REPH vs CRON Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, REPH is priced at $2.09, while CRON trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CRON's P/E ratio is -139.50. In terms of profitability, REPH's ROE is -0.22%, compared to CRON's ROE of -0.00%. Regarding short-term risk, REPH is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CRON's competition here
REPH vs EVO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EVO has a market cap of 976.8M. Regarding current trading prices, REPH is priced at $2.09, while EVO trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EVO's P/E ratio is -4.37. In terms of profitability, REPH's ROE is -0.22%, compared to EVO's ROE of -0.24%. Regarding short-term risk, REPH is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check EVO's competition here
REPH vs PETQ Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, REPH is priced at $2.09, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PETQ's P/E ratio is 83.73. In terms of profitability, REPH's ROE is -0.22%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, REPH is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PETQ's competition here
REPH vs PCRX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PCRX has a market cap of 913M. Regarding current trading prices, REPH is priced at $2.09, while PCRX trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PCRX's P/E ratio is 178.54. In terms of profitability, REPH's ROE is -0.22%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, REPH is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PCRX's competition here
REPH vs AMPH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AMPH has a market cap of 888.9M. Regarding current trading prices, REPH is priced at $2.09, while AMPH trades at $20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AMPH's P/E ratio is 12.14. In terms of profitability, REPH's ROE is -0.22%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, REPH is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AMPH's competition here
REPH vs TLRY Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TLRY has a market cap of 618.4M. Regarding current trading prices, REPH is priced at $2.09, while TLRY trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TLRY's P/E ratio is -0.35. In terms of profitability, REPH's ROE is -0.22%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, REPH is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TLRY's competition here
REPH vs BDSI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, REPH is priced at $2.09, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BDSI's P/E ratio is 6.82. In terms of profitability, REPH's ROE is -0.22%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, REPH is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check BDSI's competition here
REPH vs IRWD Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, IRWD has a market cap of 530.1M. Regarding current trading prices, REPH is priced at $2.09, while IRWD trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas IRWD's P/E ratio is 5.19. In terms of profitability, REPH's ROE is -0.22%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, REPH is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check IRWD's competition here
REPH vs EOLS Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EOLS has a market cap of 441.2M. Regarding current trading prices, REPH is priced at $2.09, while EOLS trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EOLS's P/E ratio is -10.15. In terms of profitability, REPH's ROE is -0.22%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, REPH is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check EOLS's competition here
REPH vs CGC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CGC has a market cap of 434.4M. Regarding current trading prices, REPH is priced at $2.09, while CGC trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CGC's P/E ratio is -0.77. In terms of profitability, REPH's ROE is -0.22%, compared to CGC's ROE of -0.51%. Regarding short-term risk, REPH is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CGC's competition here
REPH vs KMDA Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, KMDA has a market cap of 417.6M. Regarding current trading prices, REPH is priced at $2.09, while KMDA trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas KMDA's P/E ratio is 20.69. In terms of profitability, REPH's ROE is -0.22%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, REPH is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check KMDA's competition here
REPH vs AQST Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AQST has a market cap of 396.2M. Regarding current trading prices, REPH is priced at $2.09, while AQST trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AQST's P/E ratio is -6.54. In terms of profitability, REPH's ROE is -0.22%, compared to AQST's ROE of +1.91%. Regarding short-term risk, REPH is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AQST's competition here
REPH vs SNDL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SNDL has a market cap of 379.8M. Regarding current trading prices, REPH is priced at $2.09, while SNDL trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SNDL's P/E ratio is -48.67. In terms of profitability, REPH's ROE is -0.22%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, REPH is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SNDL's competition here
REPH vs ORGO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ORGO has a market cap of 319.1M. Regarding current trading prices, REPH is priced at $2.09, while ORGO trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ORGO's P/E ratio is -20.67. In terms of profitability, REPH's ROE is -0.22%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, REPH is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ORGO's competition here
REPH vs SIGA Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SIGA has a market cap of 314.9M. Regarding current trading prices, REPH is priced at $2.09, while SIGA trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SIGA's P/E ratio is 15.68. In terms of profitability, REPH's ROE is -0.22%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, REPH is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SIGA's competition here
REPH vs ALIM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, REPH is priced at $2.09, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ALIM's P/E ratio is 5.28. In terms of profitability, REPH's ROE is -0.22%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, REPH is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ALIM's competition here
REPH vs LNDC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, REPH is priced at $2.09, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LNDC's P/E ratio is -4.04. In terms of profitability, REPH's ROE is -0.22%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, REPH is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check LNDC's competition here
REPH vs TKNO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TKNO has a market cap of 239.1M. Regarding current trading prices, REPH is priced at $2.09, while TKNO trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TKNO's P/E ratio is -13.94. In terms of profitability, REPH's ROE is -0.22%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, REPH is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TKNO's competition here
REPH vs TYHT Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, REPH is priced at $2.09, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TYHT's P/E ratio is -1.61. In terms of profitability, REPH's ROE is -0.22%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, REPH is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TYHT's competition here
REPH vs LFCR Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LFCR has a market cap of 212.3M. Regarding current trading prices, REPH is priced at $2.09, while LFCR trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LFCR's P/E ratio is -4.46. In terms of profitability, REPH's ROE is -0.22%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, REPH is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check LFCR's competition here
REPH vs ACB Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ACB has a market cap of 199.8M. Regarding current trading prices, REPH is priced at $2.09, while ACB trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ACB's P/E ratio is -3.16. In terms of profitability, REPH's ROE is -0.22%, compared to ACB's ROE of -0.08%. Regarding short-term risk, REPH is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ACB's competition here
REPH vs EMBC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EMBC has a market cap of 196.4M. Regarding current trading prices, REPH is priced at $2.09, while EMBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EMBC's P/E ratio is 1.75. In terms of profitability, REPH's ROE is -0.22%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, REPH is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check EMBC's competition here
REPH vs DERM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DERM has a market cap of 170.1M. Regarding current trading prices, REPH is priced at $2.09, while DERM trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DERM's P/E ratio is -16.70. In terms of profitability, REPH's ROE is -0.22%, compared to DERM's ROE of -0.36%. Regarding short-term risk, REPH is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check DERM's competition here
REPH vs THTX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, REPH is priced at $2.09, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas THTX's P/E ratio is -17.84. In terms of profitability, REPH's ROE is -0.22%, compared to THTX's ROE of +0.17%. Regarding short-term risk, REPH is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check THTX's competition here
REPH vs OGI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OGI has a market cap of 152M. Regarding current trading prices, REPH is priced at $2.09, while OGI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OGI's P/E ratio is -7.20. In terms of profitability, REPH's ROE is -0.22%, compared to OGI's ROE of -0.07%. Regarding short-term risk, REPH is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check OGI's competition here
REPH vs ASRT Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ASRT has a market cap of 151.6M. Regarding current trading prices, REPH is priced at $2.09, while ASRT trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ASRT's P/E ratio is -4.23. In terms of profitability, REPH's ROE is -0.22%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, REPH is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ASRT's competition here
REPH vs CRDL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CRDL has a market cap of 120.8M. Regarding current trading prices, REPH is priced at $2.09, while CRDL trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CRDL's P/E ratio is -3.86. In terms of profitability, REPH's ROE is -0.22%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, REPH is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CRDL's competition here
REPH vs SCTL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, REPH is priced at $2.09, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SCTL's P/E ratio is -7.86. In terms of profitability, REPH's ROE is -0.22%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, REPH is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SCTL's competition here
REPH vs PROC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, REPH is priced at $2.09, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PROC's P/E ratio is 1.53. In terms of profitability, REPH's ROE is -0.22%, compared to PROC's ROE of -2.22%. Regarding short-term risk, REPH is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PROC's competition here
REPH vs OPTN Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, REPH is priced at $2.09, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OPTN's P/E ratio is -4.42. In terms of profitability, REPH's ROE is -0.22%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, REPH is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check OPTN's competition here
REPH vs ZOM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, REPH is priced at $2.09, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZOM's P/E ratio is -1.62. In terms of profitability, REPH's ROE is -0.22%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, REPH is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ZOM's competition here
REPH vs GRVI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, REPH is priced at $2.09, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas GRVI's P/E ratio is 26.05. In terms of profitability, REPH's ROE is -0.22%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, REPH is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check GRVI's competition here
REPH vs CPIX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CPIX has a market cap of 85.7M. Regarding current trading prices, REPH is priced at $2.09, while CPIX trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CPIX's P/E ratio is -11.67. In terms of profitability, REPH's ROE is -0.22%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, REPH is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CPIX's competition here
REPH vs ZYNE Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, REPH is priced at $2.09, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, REPH's ROE is -0.22%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, REPH is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ZYNE's competition here
REPH vs BGM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BGM has a market cap of 68.2M. Regarding current trading prices, REPH is priced at $2.09, while BGM trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BGM's P/E ratio is -1.17. In terms of profitability, REPH's ROE is -0.22%, compared to BGM's ROE of -0.03%. Regarding short-term risk, REPH is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check BGM's competition here
REPH vs SSIC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, REPH is priced at $2.09, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SSIC's P/E ratio is 11.93. In terms of profitability, REPH's ROE is -0.22%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, REPH is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SSIC's competition here
REPH vs VLNS Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, REPH is priced at $2.09, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas VLNS's P/E ratio is -1.03. In terms of profitability, REPH's ROE is -0.22%, compared to VLNS's ROE of N/A. Regarding short-term risk, REPH is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check VLNS's competition here
REPH vs DRRX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, REPH is priced at $2.09, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas DRRX's P/E ratio is -4.44. In terms of profitability, REPH's ROE is -0.22%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, REPH is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check DRRX's competition here
REPH vs INCR Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, INCR has a market cap of 51.9M. Regarding current trading prices, REPH is priced at $2.09, while INCR trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas INCR's P/E ratio is -4.12. In terms of profitability, REPH's ROE is -0.22%, compared to INCR's ROE of -0.09%. Regarding short-term risk, REPH is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check INCR's competition here
REPH vs JUPW Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, REPH is priced at $2.09, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas JUPW's P/E ratio is -2.41. In terms of profitability, REPH's ROE is -0.22%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, REPH is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check JUPW's competition here
REPH vs ZYBT Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ZYBT has a market cap of 42.2M. Regarding current trading prices, REPH is priced at $2.09, while ZYBT trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ZYBT's P/E ratio is -4.05. In terms of profitability, REPH's ROE is -0.22%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, REPH is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ZYBT's competition here
REPH vs IXHL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, IXHL has a market cap of 42.1M. Regarding current trading prices, REPH is priced at $2.09, while IXHL trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas IXHL's P/E ratio is -0.22. In terms of profitability, REPH's ROE is -0.22%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, REPH is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check IXHL's competition here
REPH vs QLI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, REPH is priced at $2.09, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas QLI's P/E ratio is -4.92. In terms of profitability, REPH's ROE is -0.22%, compared to QLI's ROE of -0.16%. Regarding short-term risk, REPH is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check QLI's competition here
REPH vs HEXO Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, REPH is priced at $2.09, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas HEXO's P/E ratio is -0.26. In terms of profitability, REPH's ROE is -0.22%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, REPH is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check HEXO's competition here
REPH vs SCYX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SCYX has a market cap of 27.4M. Regarding current trading prices, REPH is priced at $2.09, while SCYX trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SCYX's P/E ratio is -1.14. In terms of profitability, REPH's ROE is -0.22%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, REPH is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SCYX's competition here
REPH vs RMTI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RMTI has a market cap of 27.1M. Regarding current trading prices, REPH is priced at $2.09, while RMTI trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RMTI's P/E ratio is -4.57. In terms of profitability, REPH's ROE is -0.22%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, REPH is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check RMTI's competition here
REPH vs CYTH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, REPH is priced at $2.09, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CYTH's P/E ratio is -0.80. In terms of profitability, REPH's ROE is -0.22%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, REPH is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CYTH's competition here
REPH vs TXMD Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TXMD has a market cap of 21.8M. Regarding current trading prices, REPH is priced at $2.09, while TXMD trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TXMD's P/E ratio is 188.00. In terms of profitability, REPH's ROE is -0.22%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, REPH is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check TXMD's competition here
REPH vs EVOK Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, REPH is priced at $2.09, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas EVOK's P/E ratio is -7.97. In terms of profitability, REPH's ROE is -0.22%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, REPH is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check EVOK's competition here
REPH vs AYTU Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AYTU has a market cap of 18.6M. Regarding current trading prices, REPH is priced at $2.09, while AYTU trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AYTU's P/E ratio is -0.49. In terms of profitability, REPH's ROE is -0.22%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, REPH is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AYTU's competition here
REPH vs QNTM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, QNTM has a market cap of 17.5M. Regarding current trading prices, REPH is priced at $2.09, while QNTM trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas QNTM's P/E ratio is -0.50. In terms of profitability, REPH's ROE is -0.22%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, REPH is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check QNTM's competition here
REPH vs TLPH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, TLPH has a market cap of 16.7M. Regarding current trading prices, REPH is priced at $2.09, while TLPH trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas TLPH's P/E ratio is -2.91. In terms of profitability, REPH's ROE is -0.22%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, REPH is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check TLPH's competition here
REPH vs OPTH Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, OPTH has a market cap of 15.8M. Regarding current trading prices, REPH is priced at $2.09, while OPTH trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas OPTH's P/E ratio is -4.00. In terms of profitability, REPH's ROE is -0.22%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, REPH is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check OPTH's competition here
REPH vs ACRX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, REPH is priced at $2.09, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ACRX's P/E ratio is -0.31. In terms of profitability, REPH's ROE is -0.22%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, REPH is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check ACRX's competition here
REPH vs COSM Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, COSM has a market cap of 13.4M. Regarding current trading prices, REPH is priced at $2.09, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas COSM's P/E ratio is -0.34. In terms of profitability, REPH's ROE is -0.22%, compared to COSM's ROE of -0.96%. Regarding short-term risk, REPH is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check COSM's competition here
REPH vs BFRI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, BFRI has a market cap of 11.3M. Regarding current trading prices, REPH is priced at $2.09, while BFRI trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas BFRI's P/E ratio is -0.90. In terms of profitability, REPH's ROE is -0.22%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, REPH is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check BFRI's competition here
REPH vs AGRX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, REPH is priced at $2.09, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas AGRX's P/E ratio is -0.89. In terms of profitability, REPH's ROE is -0.22%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, REPH is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check AGRX's competition here
REPH vs NLTX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, REPH is priced at $2.09, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas NLTX's P/E ratio is -0.28. In terms of profitability, REPH's ROE is -0.22%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, REPH is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check NLTX's competition here
REPH vs YCBD Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, YCBD has a market cap of 7.5M. Regarding current trading prices, REPH is priced at $2.09, while YCBD trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas YCBD's P/E ratio is 0.29. In terms of profitability, REPH's ROE is -0.22%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, REPH is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check YCBD's competition here
REPH vs LCI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, REPH is priced at $2.09, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas LCI's P/E ratio is -0.04. In terms of profitability, REPH's ROE is -0.22%, compared to LCI's ROE of +1.66%. Regarding short-term risk, REPH is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check LCI's competition here
REPH vs ADMP Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, REPH is priced at $2.09, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ADMP's P/E ratio is -0.08. In terms of profitability, REPH's ROE is -0.22%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, REPH is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ADMP's competition here
REPH vs MNK Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, REPH is priced at $2.09, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas MNK's P/E ratio is -0.44. In terms of profitability, REPH's ROE is -0.22%, compared to MNK's ROE of -0.26%. Regarding short-term risk, REPH is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check MNK's competition here
REPH vs GELS Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, GELS has a market cap of 4.4M. Regarding current trading prices, REPH is priced at $2.09, while GELS trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas GELS's P/E ratio is -0.94. In terms of profitability, REPH's ROE is -0.22%, compared to GELS's ROE of -0.43%. Regarding short-term risk, REPH is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check GELS's competition here
REPH vs FLGC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, REPH is priced at $2.09, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas FLGC's P/E ratio is -0.19. In terms of profitability, REPH's ROE is -0.22%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, REPH is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check FLGC's competition here
REPH vs PLXP Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, REPH is priced at $2.09, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PLXP's P/E ratio is -0.22. In terms of profitability, REPH's ROE is -0.22%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, REPH is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check PLXP's competition here
REPH vs RDHL Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, RDHL has a market cap of 2.5M. Regarding current trading prices, REPH is priced at $2.09, while RDHL trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas RDHL's P/E ratio is N/A. In terms of profitability, REPH's ROE is -0.22%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, REPH is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check RDHL's competition here
REPH vs ATNX Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, REPH is priced at $2.09, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas ATNX's P/E ratio is -0.02. In terms of profitability, REPH's ROE is -0.22%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, REPH is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check ATNX's competition here
REPH vs CPHI Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, CPHI has a market cap of 2.3M. Regarding current trading prices, REPH is priced at $2.09, while CPHI trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas CPHI's P/E ratio is -1.32. In terms of profitability, REPH's ROE is -0.22%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, REPH is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check CPHI's competition here
REPH vs PROCW Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, REPH is priced at $2.09, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas PROCW's P/E ratio is N/A. In terms of profitability, REPH's ROE is -0.22%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, REPH is more volatile compared to PROCW. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check PROCW's competition here
REPH vs SNOA Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, SNOA has a market cap of 1.9M. Regarding current trading prices, REPH is priced at $2.09, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas SNOA's P/E ratio is -0.57. In terms of profitability, REPH's ROE is -0.22%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, REPH is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check SNOA's competition here
REPH vs UPC Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, UPC has a market cap of 1.9M. Regarding current trading prices, REPH is priced at $2.09, while UPC trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas UPC's P/E ratio is -0.42. In terms of profitability, REPH's ROE is -0.22%, compared to UPC's ROE of -0.07%. Regarding short-term risk, REPH is more volatile compared to UPC. This indicates potentially higher risk in terms of short-term price fluctuations for REPH.Check UPC's competition here
REPH vs APUS Comparison June 2026
REPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REPH stands at 177.4M. In comparison, APUS has a market cap of 1.6M. Regarding current trading prices, REPH is priced at $2.09, while APUS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REPH currently has a P/E ratio of -8.04, whereas APUS's P/E ratio is -0.47. In terms of profitability, REPH's ROE is -0.22%, compared to APUS's ROE of -0.55%. Regarding short-term risk, REPH is less volatile compared to APUS. This indicates potentially lower risk in terms of short-term price fluctuations for REPH.Check APUS's competition here